Temporal trends of COVID-19 antibodies in vaccinated healthcare workers undergoing repeated serological sampling: An individual-level analysis within 13 months in the ORCHESTRA cohort.
COVID-19 vaccination
antibodies
health care workers
serial serology
temporal trends
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
10
2022
accepted:
13
12
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
1
2
2023
Statut:
epublish
Résumé
We investigated changes in serologic measurements after COVID-19 vaccination in 19,422 subjects. An individual-level analysis was performed on standardized measurements. Age, infection, vaccine doses, time between doses and serologies, and vaccine type were associated with changes in serologic levels within 13 months. Persistence of vaccine immunization is key for COVID-19 prevention. We investigated the difference between two serologic measurements of anti-COVID-19 S1 antibodies in an individual-level analysis on 19,422 vaccinated healthcare workers (HCW) from Italy, Spain, Romania, and Slovakia, tested within 13 months from first dose. Differences in serologic levels were divided by the standard error of the cohort-specific distribution, obtaining standardized measurements. We fitted multivariate linear regression models to identify predictors of difference between two measurements. We observed a progressively decreasing difference in serologic levels from <30 days to 210-240 days. Age was associated with an increased difference in serologic levels. There was a greater difference between the two serologic measurements in infected HCW than in HCW who had never been infected; before the first measurement, infected HCW had a relative risk (RR) of 0.81 for one standard deviation in the difference [95% confidence interval (CI) 0.78-0.85]. The RRs for a 30-day increase in time between first dose and first serology, and between the two serologies, were 1.08 (95% CI 1.07-1.10) and 1.04 (95% CI 1.03-1.05), respectively. The first measurement was a strong predictor of subsequent antibody decrease (RR 1.60; 95% CI 1.56-1.64). Compared with Comirnaty, Spikevax (RR 0.83, 95% CI 0.75-0.92) and mixed vaccines (RR 0.61, 95% CI 0.51-0.74) were smaller decrease in serological level (RR 0.46; 95% CI 0.40-0.54). Age, COVID-19 infection, number of doses, time between first dose and first serology, time between serologies, and type of vaccine were associated with differences between the two serologic measurements within a 13-month period.
Sections du résumé
Short summary
We investigated changes in serologic measurements after COVID-19 vaccination in 19,422 subjects. An individual-level analysis was performed on standardized measurements. Age, infection, vaccine doses, time between doses and serologies, and vaccine type were associated with changes in serologic levels within 13 months.
Background
Persistence of vaccine immunization is key for COVID-19 prevention.
Methods
We investigated the difference between two serologic measurements of anti-COVID-19 S1 antibodies in an individual-level analysis on 19,422 vaccinated healthcare workers (HCW) from Italy, Spain, Romania, and Slovakia, tested within 13 months from first dose. Differences in serologic levels were divided by the standard error of the cohort-specific distribution, obtaining standardized measurements. We fitted multivariate linear regression models to identify predictors of difference between two measurements.
Results
We observed a progressively decreasing difference in serologic levels from <30 days to 210-240 days. Age was associated with an increased difference in serologic levels. There was a greater difference between the two serologic measurements in infected HCW than in HCW who had never been infected; before the first measurement, infected HCW had a relative risk (RR) of 0.81 for one standard deviation in the difference [95% confidence interval (CI) 0.78-0.85]. The RRs for a 30-day increase in time between first dose and first serology, and between the two serologies, were 1.08 (95% CI 1.07-1.10) and 1.04 (95% CI 1.03-1.05), respectively. The first measurement was a strong predictor of subsequent antibody decrease (RR 1.60; 95% CI 1.56-1.64). Compared with Comirnaty, Spikevax (RR 0.83, 95% CI 0.75-0.92) and mixed vaccines (RR 0.61, 95% CI 0.51-0.74) were smaller decrease in serological level (RR 0.46; 95% CI 0.40-0.54).
Conclusions
Age, COVID-19 infection, number of doses, time between first dose and first serology, time between serologies, and type of vaccine were associated with differences between the two serologic measurements within a 13-month period.
Identifiants
pubmed: 36713452
doi: 10.3389/fimmu.2022.1079884
pmc: PMC9875291
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1079884Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Collatuzzo, De Palma, Violante, Porru, Larese Filon, Fabianova, Violán, Vimercati, Leustean, Rodriguez-Suarez, Sansone, Sala, Zunarelli, Lodi, Monaco, Spiteri, Negro, Beresova, Carrasco-Ribelles, Tafuri, Asafo, Ditano, Abedini and Boffetta.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Infect Dis. 2022 May 7;22(1):439
pubmed: 35525973
Mayo Clin Proc. 2015 Dec;90(12):1659-62
pubmed: 26422242
JAMA Pediatr. 2021 Feb 1;175(2):125-126
pubmed: 32926083
Lancet Infect Dis. 2021 Feb;21(2):e26-e35
pubmed: 33125914
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Front Immunol. 2022 Jan 27;13:829665
pubmed: 35154152
BMJ. 2021 Aug 18;374:n1868
pubmed: 34407952
Expert Rev Vaccines. 2016 Dec;15(12):1519-1533
pubmed: 27267203
Sci Rep. 2021 Mar 11;11(1):5788
pubmed: 33707646
Microbiol Spectr. 2021 Sep 3;9(1):e0034121
pubmed: 34346750
J Autoimmun. 2012 May;38(2-3):J282-91
pubmed: 22225601
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7
pubmed: 19416838
Eur J Immunol. 2009 Aug;39(8):2100-5
pubmed: 19637203
Vaccine. 2014 May 23;32(25):2948-57
pubmed: 24709587
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705
pubmed: 34882654
Front Immunol. 2021 Apr 12;12:669339
pubmed: 33912196
Int J Infect Dis. 2008 May;12(3):233-8
pubmed: 17913533
JAMA. 2021 Nov 23;326(20):2043-2054
pubmed: 34734975
Nat Commun. 2022 Feb 16;13(1):907
pubmed: 35173150
Med Lav. 2022 Apr 26;113(2):e2022022
pubmed: 35481576
Vaccines (Basel). 2021 Sep 04;9(9):
pubmed: 34579226
J Med Virol. 2022 Jan;94(1):279-286
pubmed: 34468990
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
BMJ. 2021 Jun 29;373:n1645
pubmed: 34187932
Hum Vaccin Immunother. 2018 Mar 4;14(3):772-789
pubmed: 28787234
PLoS Med. 2022 May 17;19(5):e1003991
pubmed: 35580156
Vaccine. 2016 Dec 20;34(52):6707-6714
pubmed: 27773475
Hum Vaccin Immunother. 2016 Nov;12(11):2881-2901
pubmed: 27455345
Front Med (Lausanne). 2022 Feb 02;9:821522
pubmed: 35187005
Front Immunol. 2021 Dec 22;12:802858
pubmed: 35003131
Front Immunol. 2022 Jan 31;13:827306
pubmed: 35173736
Cochrane Database Syst Rev. 2020 Apr 20;4:CD004407
pubmed: 32309885
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169
pubmed: 34437521
Front Immunol. 2019 Mar 27;10:594
pubmed: 30972078
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
J Infect Chemother. 2022 Jun;28(6):802-805
pubmed: 35288023
Front Immunol. 2022 Sep 29;13:986085
pubmed: 36248889
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347